echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > JCEM: Cardiovascular benefits of empagliflozin are associated with gut microbiota and plasma metabolites in patients with type 2 diabetes

    JCEM: Cardiovascular benefits of empagliflozin are associated with gut microbiota and plasma metabolites in patients with type 2 diabetes

    • Last Update: 2022-05-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Cardiovascular benefits of empagliflozin in patients with type 2 diabetes ( T2DM) have been reported; however, the underlying mechanisms remain unknown


    diabetes blood vessels

    The study was a randomized, open-label, 3-month, two-group clinical trial of 76 untreated T2DM patients with cardiovascular risk factors


    metformin

    We explored changes in clinical parameters associated with glucose metabolism and cardiovascular disease risk factors and analyzed gut microbiota using 16S rRNA gene sequencing and plasma metabolites using LC-MS


    The researchers found that both groups had significant and similar reductions in glycated hemoglobin levels, as well as ease in glucose metabolism


    CONCLUSIONS: Empagliflozin may be the treatment of choice for patients with type 2 diabetes at risk for cardiovascular disease; its cardiovascular benefits may be related to changes in gut microbiota and plasma metabolites


    Empagliflozin may be the treatment of choice in patients with type 2 diabetes at risk for cardiovascular disease; its cardiovascular benefits may be related to changes in gut microbiota and plasma metabolites


    Original source:

    Xinru Deng.


    Xinru Deng.
    et al.
    Cardiovascular benefits of empagliflozin are associated with gut microbiota and plasma metabolites in type 2 diabetes .
    JCEM.
    2022.
    https://academic.
    oup.
    com/jcem/advance-article/doi/10.
    1210/clinem/dgac210 /6565990 Cardiovascular benefits of empagliflozin are associated with gut microbiota and plasma metabolites in type 2 diabetes

    Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.